Guselkumab Continues Winning Streak in Crohn's Disease
Dual-acting IL-23 inhibitor tops placebo, ustekinumab in phase III trials
Source: medpagetoday.com
📰 Stool Frequency News
Stool Frequency News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Stool Frequency. Real-time updates on events, politics, business and more.
Why holding back your urge to poop can wreak havoc on your insides – a gastroenterologist explains
The golden rule of gastroenterology is to always heed the ‘call to stool’ when the urge strikes.
Source: theconversation.com
Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies
Gilead Sciences K.K.(Headquarter: Chiyoda-ku, Tokyo, General Manager: Kennet Brysting, “Gilead”), Eisai Co., Ltd.
Source: pressreleasepoint.com
Psychometric properties of the EORTC-QLQ-CR29 tool
Validity and reliability of the Amharic version of EORTC-QLQ-CR29 among colorectal cancer patients in Ethiopia
Zuid Holland Addis Ababa Ethiopian Federal Ministry Of Health World Health Organization Eastern Africa Saharan Africa
Source: dovepress.com
Risankizumab Has Early and Lasting Benefits in Crohn's Disease
Risankizumab takes effect within the first few weeks and has enduring effects in Crohns disease, phase 3 trials suggest.
Source: medscape.com